Performance Study of the Cobas® BV/CV Test on Samples From Participants With and Without Symptoms of Bacterial Vaginosis and Candida Vaginitis

Last updated: June 6, 2025
Sponsor: Hoffmann-La Roche
Overall Status: Active - Recruiting

Phase

N/A

Condition

Systemic Candidiasis

Sexually Transmitted Diseases (Stds)

Vaginitis

Treatment

Hologic Aptima BV Assay

BD Max™ Vaginal Panel

Cepheid Xpert Xpress MVP

Clinical Study ID

NCT06975436
RD006770
  • Ages > 14
  • Female
  • Accepts Healthy Volunteers

Study Summary

In the clinical performance part of this study, prospectively acquired clinician-collected and clinician-instructed, self-collected vaginal swab specimens collected in cobas® PCR Media will be taken from a minimum of 500 symptomatic individuals with a clinical presentation consistent with vaginitis, vaginosis, or both. Additionally, a minimum of 100 asymptomatic individuals will also be enrolled in the study. The cobas® BV/CV assay amplifies and detects the deoxyribonucleic acid (DNA) of pathogens associated with bacterial vaginosis (BV) and candida vaginitis (CV). The BV results will be compared with the patient infection status (PIS) established by using 3 Food and Drug Administration (FDA)-cleared commercial assays, and the CV results will be compared with the PIS established with the use of culture plus MALDI-TOF (matrix-assisted laser desorption/ionization time-of-flight).

The primary objective of the clinical performance study is to evaluate the performance (sensitivity and specificity) of cobas® BV/CV to determine the presence of BV and/or CV in the intended use patient population when being tested on cobas® 6800/8800 systems. The secondary objective is to evaluate the equivalency of cobas® BV/CV between the cobas® 5800 system and cobas® 6800/8800 systems.

Eligibility Criteria

Inclusion

Inclusion Criteria:

Inclusion Criteria for Symptomatic Participants:

  • Symptomatic participants with a clinical presentation consistent with vaginitis,vaginosis, or both; symptoms may include abnormal vaginal discharge, painful orfrequent urination, vaginal itching or burning or irritation, painful oruncomfortable intercourse, and/or abnormal vaginal odor.

  • Participants aged 14 years or older who are willing and able to provide written,informed consent; for pediatric participants, written assent and parent/legalguardian consent, as applicable by the institutional review board/ethics committee (IRB/EC).

Inclusion Criteria for Asymptomatic Participants:

  • Apparently healthy participants aged 14 years or older who are willing and able toprovide written, informed consent; for pediatric participants, written assent andparent/legal guardian consent, as applicable by the IRB/EC.

Exclusion

Exclusion Criteria:

Exclusion Criteria for Symptomatic Participants:

  • Participants not meeting the above described inclusion criteria will be excludedfrom the study.

  • Use of any azole-containing antimicrobial (oral or vaginal) within the 7 days priorto study enrollment.

  • Prior enrollment in this study.

  • Use of any lubricants (eg, Replens, RepHresh) within 3 days prior to samplecollection

  • Use of douches, vaginal deodorizers, or other intravaginal products within 3 daysprior to sample collection. The use of tampons or pads during menses should not beconsidered exclusionary criteria.

  • Contraindication to vaginal swab sampling.

  • Asymptomatic participants who do not have any signs or symptoms consistent withvaginitis, vaginosis, or both, as described above.

Exclusion Criteria for Asymptomatic Participants:

  • Prior enrollment in this study.

  • Participants with a clinical presentation consistent with vaginitis, vaginosis, orboth; symptoms may include abnormal vaginal discharge, painful or frequenturination, vaginal itching or burning or irritation, painful or uncomfortableintercourse, and/or abnormal vaginal odor.

Study Design

Total Participants: 600
Treatment Group(s): 4
Primary Treatment: Hologic Aptima BV Assay
Phase:
Study Start date:
December 30, 2024
Estimated Completion Date:
June 30, 2025

Connect with a study center

  • Diagnostic Consultative Center "Ascendent" Ltd.

    Sofia, 1202
    Bulgaria

    Active - Recruiting

  • Centre Hospitalier Universitaire Vaudois (Chuv)

    Lausanne, 1011
    Switzerland

    Active - Recruiting

  • Matrix Clinical Research

    Los Angeles, California 90057-4103
    United States

    Completed

  • M3 Wake Research - San Diego at Convoy

    San Diego, California 92111
    United States

    Completed

  • Red Rocks OBGYN

    Lakewood, Colorado 80228
    United States

    Completed

  • Altus Research

    Lake Worth, Florida 33461
    United States

    Completed

  • Washington University

    Saint Louis, Missouri 63110
    United States

    Completed

  • Eastern Carolina Women's Center

    New Bern, North Carolina 28562
    United States

    Completed

  • Unified Women's Clinical Research/Lyndhurst

    Winston-Salem, North Carolina 27103
    United States

    Completed

  • Planned Parenthood Gulf Coast

    Houston, Texas 77023
    United States

    Completed

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.